ES2495266B1 - Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer - Google Patents

Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer Download PDF

Info

Publication number
ES2495266B1
ES2495266B1 ES201330187A ES201330187A ES2495266B1 ES 2495266 B1 ES2495266 B1 ES 2495266B1 ES 201330187 A ES201330187 A ES 201330187A ES 201330187 A ES201330187 A ES 201330187A ES 2495266 B1 ES2495266 B1 ES 2495266B1
Authority
ES
Spain
Prior art keywords
igf
diagnosis
reagent
alzheimer disease
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201330187A
Other languages
English (en)
Other versions
ES2495266A1 (es
ES2495266B8 (es
Inventor
Angel TRUEBA SAIZ
Ignacio Torres Aleman
Carmen CAVADA MARTINEZ
Angel NUÑEZ MOLINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Autonoma de Madrid filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201330187A priority Critical patent/ES2495266B8/es
Priority to PCT/ES2014/070103 priority patent/WO2014125150A1/es
Priority to EP14751079.6A priority patent/EP2957910A4/en
Priority to US14/767,490 priority patent/US20150374852A1/en
Publication of ES2495266A1 publication Critical patent/ES2495266A1/es
Publication of ES2495266B1 publication Critical patent/ES2495266B1/es
Application granted granted Critical
Publication of ES2495266B8 publication Critical patent/ES2495266B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/372—Analysis of electroencephalograms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A61B5/384—Recording apparatus or displays specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/40—Animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2503/00—Evaluating a particular growth phase or type of persons or animals
    • A61B2503/42—Evaluating a particular growth phase or type of persons or animals for laboratory research
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/369—Electroencephalography [EEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)

Abstract

Uso de IGF-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer.#La presente invención se refiere al uso del factor de crecimiento insulínico tipo 1 (IGF-1) como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer, así como a un kit que comprende IGF-1 y un sedante y su uso en el diagnóstico y/o pronóstico precoz de la enfermedad de Alzheimer.

Description



imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)



  1. imagen1
    imagen2
ES201330187A 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer Expired - Fee Related ES2495266B8 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201330187A ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
PCT/ES2014/070103 WO2014125150A1 (es) 2013-02-13 2014-02-12 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
EP14751079.6A EP2957910A4 (en) 2013-02-13 2014-02-12 USE OF IGF-1 AS AN EARLY DIAGNOSTIC AND / OR PROGNOSTIC REAGENT FOR ALZHEIMER'S DISEASE
US14/767,490 US20150374852A1 (en) 2013-02-13 2014-02-12 Use of IGF-1 as a Reagent for Early Diagnosis and/or Prognosis of Alzheimer Disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330187A ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Publications (3)

Publication Number Publication Date
ES2495266A1 ES2495266A1 (es) 2014-09-16
ES2495266B1 true ES2495266B1 (es) 2015-06-25
ES2495266B8 ES2495266B8 (es) 2015-11-12

Family

ID=51353508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330187A Expired - Fee Related ES2495266B8 (es) 2013-02-13 2013-02-13 Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer

Country Status (4)

Country Link
US (1) US20150374852A1 (es)
EP (1) EP2957910A4 (es)
ES (1) ES2495266B8 (es)
WO (1) WO2014125150A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017470A (en) * 1984-10-29 1991-05-21 Chaovanee Aroonsakul Method of diagnosing alzheimer's disease and senile dementia
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
KR100941597B1 (ko) 2001-02-27 2010-02-11 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한알쯔하이머병 진단
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
EP1817050B1 (en) * 2004-12-03 2015-04-15 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
JP2010517540A (ja) * 2007-02-08 2010-05-27 ポウムリ リミテッド 神経変性疾患の診断法
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2008153929A1 (en) * 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Igf for the treatment of rett syndrome and synaptic disorders

Also Published As

Publication number Publication date
ES2495266A1 (es) 2014-09-16
ES2495266B8 (es) 2015-11-12
WO2014125150A1 (es) 2014-08-21
US20150374852A1 (en) 2015-12-31
EP2957910A4 (en) 2016-09-14
EP2957910A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
ES2533145B1 (es) Procedimiento cosmético para reducir el tejido adiposo subcutáneo
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
ES2603153T3 (es) Dispositivo de procesamiento de imágenes, procedimiento de procesamiento de imágenes, programa y soporte de grabación
PA8747701A1 (es) Métodos de marcación con flúor radioactivo
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
JP2014520786A5 (es)
ES2524164B1 (es) Pronóstico de respuesta al tratamiento con anti-tnfalfa en pacientes de artritis reumatoide
ES2414290R1 (es) Metodo para el diagnostico y/o pronostico de dano renal agudo
CO7160087A2 (es) Nalmefeno para reducir el consumo de alcohol en poblaciones diana específicas
JP2016505506A5 (es)
ES2470816B1 (es) Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
ES2495266B1 (es) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
ES2527010T3 (es) Complejo de flurano
ES2493069T3 (es) CYBP como marcador del cáncer de pulmón
ES2427714B1 (es) Nuevos derivados clorados de BODIPY
ES2565198T3 (es) Metapneumovirus aviar en oncólisis
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
ES2523903B1 (es) Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática
ES2521990B2 (es) Uso de quitosano para aumentar la formación de apresorios, el parasitismo de nematodos fitopatógenos y la colonización rizosférica por Pochonia chlamydosporia
ES2432533B1 (es) Metodo para el diagnóstico y/o pronóstico de daño renal agudo
ES2426539B1 (es) Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
ES2461016B1 (es) Método para el diagnóstico y/o pronóstico de obesidad mórbida
ES2434106B1 (es) Metodo para el diagnóstico y/o pronóstico de daño renal agudo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2495266

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150625

FD2A Announcement of lapse in spain

Effective date: 20210915